Yokota M, Takeda U, Odaki M, Sasaki H, Niizato T, Kawaoto H, Watanabe H, Ishiwatari N, Hayasaka H, Koeda T
Jpn J Antibiot. 1984 Aug;37(8):1513-25.
Miocamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. At previous study, the acute and subacute toxicity of Mb1 and acute toxicity of Mb2 were performed that those metabolites did not exhibit any lethal toxicity even at the maximum physically applicable dose. The object of this study was to examine subacute toxicity in male and female rats after repeated p.o. administration of Mb2 for 5 weeks at a daily dosage of 125, 250, 500 and 1,000 mg/kg. It is, therefore, concluded that Mb2 exerted no toxic effects in this subacute toxicity.
麦白霉素（MOM）是麦迪霉素的衍生物，麦迪霉素是一种大环内酯类抗生素，可代谢为4种主要代谢产物Mb1、Mb2、Mb6和Mb12。在之前的研究中，对Mb1进行了急性和亚急性毒性试验，对Mb2进行了急性毒性试验，结果表明，即使在最大实际可用剂量下，这些代谢产物也未表现出任何致死毒性。本研究的目的是检查雄性和雌性大鼠在每日口服剂量为125、250、500和1000mg/kg的情况下，重复口服Mb2 5周后的亚急性毒性。因此，得出结论，Mb2在该亚急性毒性试验中未产生毒性作用。
